Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK

CONCLUSION: In Japanese eyes with PCV, brolucizumab q12w/q8w monotherapy resulted in robust and consistent BCVA gains that were comparable to q8w aflibercept dosing. Anatomical outcomes favoured brolucizumab over aflibercept, with 76% of brolucizumab participants maintained on q12w dosing after loading to week 48.PMID:34301613 | DOI:10.1136/bjophthalmol-2021-319090

Source: The British Journal of Ophthalmology - July 24, 2021 Category: Opthalmology Authors: Yuichiro Ogura Glenn J Jaffe Chui Ming Gemmy Cheung Gregg T Kokame Tomohiro Iida Kanji Takahashi Won Ki Lee Andrew A Chang Jordi Mon és Divya D'Souza Georges Weissgerber Kinfemichael Gedif Adrian Koh Source Type: research